You are in: eMedicine Specialties > Neurology > Inflammatory and Demyelinating Diseases Ankylosing SpondylitisArticle Last Updated: Jan 8, 2007AUTHOR AND EDITOR INFORMATIONAuthor: Alan Schaffert, MD, Former Chief of Staff, Department of Medicine, Doctor's Medical Center of Modesto; Clinical Assistant Professor, University of California at Davis Alan Schaffert is a member of the following medical societies: American Academy of Neurology, American Association of Neuromuscular and Electrodiagnostic Medicine, California Medical Association, and National Stroke Association Editors: Rodrigo O Kuljis, MD, Esther Lichtenstein Professor of Psychiatry and Neurology, Director, Division of Cognitive and Behavioral Neurology, Department of Neurology, University of Miami School of Medicine; Francisco Talavera, PharmD, PhD, Senior Pharmacy Editor, eMedicine; Florian P Thomas, MD, MA, PhD, Drmed, Director, Spinal Cord Injury Unit, St Louis Veterans Affairs Medical Center; Director, National MS Society Multiple Sclerosis Center; Associate Program Director, Professor, Department of Neurology and Psychiatry, Associate Professor, Institute for Molecular Virology, and Department of Molecular Microbiology and Immunology, St Louis University; Selim R Benbadis, MD, Professor, Director of Comprehensive Epilepsy Program, Departments of Neurology and Neurosurgery, University of South Florida School of Medicine, Tampa General Hospital; Nicholas Y Lorenzo, MD, Chief Editor, eMedicine Neurology; Consulting Staff, Neurology Specialists and Consultants Author and Editor Disclosure Synonyms and related keywords: ankylosing spondylitis, Marie-Strümpell arthritis, Bechterew disease, spondyloarthritis, spondyloarthropathy, chronic inflammatory conditions, AS, inflammation of the joints, inflammation of the tendons, inflammation of the ligaments, iritis, uveitis, aortitis, pulmonary fibrosis, amyloidosis, inflammatory bowel disease INTRODUCTIONBackgroundSpondyloarthritis or spondyloarthropathy refers to a group of chronic inflammatory conditions affecting the joints, tendon and ligament attachments, and sometimes nonskeletal structures. Ankylosing spondylitis (AS) is one of these inflammatory diseases. It primarily affects the axial joints, including the spine and sacroiliac joints. It causes eventual fusion of the spine. Peripheral joints may be involved. PathophysiologyInflammation at the sites of insertion of ligaments and tendons in the bones is the primary pathological process. Reactive bone growth occurs that is cumulative with each new attack. The disorder is predominantly skeletal, with ankylosis of the spine; involvement of hips, knees, and occasionally small joints; and plantar fasciitis. Nonskeletal problems associated with AS may include iritis, uveitis, aortitis, pulmonary fibrosis, amyloidosis, and inflammatory bowel disease. Neurological complications include C1-C2 subluxation, tendency to spinal fractures with minor trauma, spinal stenosis in the cervical or lumbar regions, chronic inflammatory cauda equina syndrome, and radiculopathy secondary to fracture or compression. FrequencyUnited StatesIn the general population, 1.4% are affected. SexMale-to-female ratio is approximately 3:1. AgePeak onset is in adolescents and adults aged 15-30 years. A juvenile form also exists. CLINICALHistoryPatients typically present in their late teens or twenties. Large joints of the lower extremities are involved more commonly in the juvenile form than in the adult form.
Physical
Causes
DIFFERENTIALSCervical Spondylosis: Diagnosis and Management Spinal Cord Hemorrhage Spinal Cord Infarction Spinal Epidural Abscess
|
| Drug Name | Ibuprofen (Motrin, Advil, Haltran, Nuprin) |
|---|---|
| Description | Inhibits inflammatory reactions and pain by decreasing activity of enzyme cyclooxygenase, thus inhibiting prostaglandin synthesis. |
| Adult Dose | 200-800 mg PO q6-8h while symptoms persist; not to exceed 3.2 g/d |
| Pediatric Dose | <6 months: Not established 6 months to 12 years: 30-70 mg/kg/d PO divided tid/qid; start at lower end of range and titrate upward; not to exceed 2.4 g/d >12 years: Administer as in adults |
| Contraindications | Documented hypersensitivity; because of potential cross-sensitivity to other NSAIDs, do not give these agents to patients in whom aspirin, iodides, or other NSAIDs have induced symptoms of asthma, rhinitis, urticaria, nasal polyps, angioedema, bronchospasm, or other symptoms of allergic or anaphylactoid reactions |
| Interactions | Probenecid may increase concentrations and possibly toxicity; may decrease effects of loop diuretics; may increase serum lithium levels and risks of methotrexate toxicity (eg, stomatitis, bone marrow suppression, nephrotoxicity) Coadministration with anticoagulants may prolong prothrombin time (PT); consider effects that NSAIDs have on platelet function and gastric mucosa; Monitor PT and patients closely, and instruct patients to watch for signs and symptoms of bleeding |
| Pregnancy | B - Usually safe but benefits must outweigh the risks. |
| Precautions | Acute renal insufficiency, interstitial nephritis, hyperkalemia, hyponatremia, and renal papillary necrosis may occur; patients with preexisting renal disease or compromised renal perfusion are at greatest risk of acute renal failure Low WBC counts are rare and transient; they usually return to normal as therapy continues; persistent leukopenia, granulocytopenia, or thrombocytopenia warrants further evaluation and may require discontinuing drug Perform ophthalmological studies in patients who develop eye complaints during therapy; effects include blurred or diminished vision, scotomata, changes in color vision, corneal deposits, and retinal disturbances (including maculae); discontinue therapy if ocular changes are noted; blurred vision may be significant and warrants thorough examination, including central visual fields and color vision testing; these changes may be asymptomatic, and thus periodic eye examinations should be performed in patients on prolonged therapy |
| Drug Name | Naproxen (Aleve, Anaprox, Naprelan, Naprosyn) |
|---|---|
| Description | Relieves mild to moderately severe pain and inhibits inflammatory reactions, probably by decreasing activity of enzyme cyclooxygenase, thus inhibiting prostaglandin synthesis. |
| Adult Dose | 250-500 mg PO bid; may increase to 1.5 g/d for limited periods; generally, not to exceed 1.25 g/d |
| Pediatric Dose | <2 years: Not established > 2 years: 2.5 mg/kg/dose PO; not to exceed 10 mg/kg/d |
| Contraindications | Documented hypersensitivity |
| Interactions | Probenecid may increase concentrations and possibly toxicity; may decrease effects of loop diuretics; may increase serum lithium levels and risks of methotrexate toxicity (eg, stomatitis, bone marrow suppression, nephrotoxicity) Coadministration with anticoagulants may prolong prothrombin time (PT); consider effects that NSAIDs have on platelet function and gastric mucosa; Monitor PT and patients closely, and instruct patients to watch for signs and symptoms of bleeding |
| Pregnancy | B - Usually safe but benefits must outweigh the risks. |
| Precautions | Acute renal insufficiency, interstitial nephritis, hyperkalemia, hyponatremia, and renal papillary necrosis may occur; patients with preexisting renal disease or compromised renal perfusion are at greatest risk of acute renal failure Low WBC counts are rare and transient; they usually return to normal as therapy continues; persistent leukopenia, granulocytopenia, or thrombocytopenia warrants further evaluation and may require discontinuing drug Perform ophthalmological studies in patients who develop eye complaints during therapy; effects include blurred or diminished vision, scotomata, changes in color vision, corneal deposits, and retinal disturbances (including maculae); discontinue therapy if ocular changes are noted; blurred vision may be significant and warrants thorough examination, including central visual fields and color vision testing; these changes may be asymptomatic, and thus periodic eye examinations should be performed in patients on prolonged therapy |
| Drug Name | Diclofenac (Voltaren) |
|---|---|
| Description | Has analgesic, antipyretic, and anti-inflammatory activity. Inhibits inflammatory reactions and pain, probably by decreasing activity of enzyme cyclooxygenase, thus inhabiting prostaglandin synthesis. Doses above stated maximum generally do not increase effectiveness. |
| Adult Dose | 25 mg PO bid/tid; if well tolerated, increase daily dose by 25 or 50 mg at weekly intervals until satisfactory response obtained; not to exceed 150-200 mg/d |
| Pediatric Dose | <14 years: Not established >14 years: Administer as in adults |
| Contraindications | Documented hypersensitivity Because of potential cross-sensitivity to other NSAIDs, do not give these agents to patients with hypersensitivity to aspirin, iodides, or other NSAIDs |
| Interactions | Probenecid may increase concentrations and possibly toxicity; may decrease effects of loop diuretics; may increase serum lithium levels and risks of methotrexate toxicity (eg, stomatitis, bone marrow suppression, nephrotoxicity) Coadministration with anticoagulants may prolong prothrombin time (PT); consider effects that NSAIDs have on platelet function and gastric mucosa; Monitor PT and patients closely, and instruct patients to watch for signs and symptoms of bleeding |
| Pregnancy | B - Usually safe but benefits must outweigh the risks. |
| Precautions | Acute renal insufficiency, interstitial nephritis, hyperkalemia, hyponatremia, and renal papillary necrosis may occur; patients with preexisting renal disease or compromised renal perfusion are at greatest risk of acute renal failure Low WBC counts are rare and transient; they usually return to normal as therapy continues; persistent leukopenia, granulocytopenia, or thrombocytopenia warrants further evaluation and may require discontinuing drug Perform ophthalmological studies in patients who develop eye complaints during therapy; effects include blurred or diminished vision, scotomata, changes in color vision, corneal deposits, and retinal disturbances (including maculae); discontinue therapy if ocular changes are noted; blurred vision may be significant and warrants thorough examination, including central visual fields and color vision testing; these changes may be asymptomatic, and thus periodic eye examinations should be performed in patients on prolonged therapy |
These agents inhibit the activity of cytokine TNF-alpha. Indications are a definitive diagnosis, active and refractory disease, with failure of conservative treatment. Treatment should be discontinued for patients who do not respond within after 6-12 weeks. Before use, refer to current practice guidelines for more complete discussions.
| Drug Name | Infliximab (Remicade) |
|---|---|
| Description | Chimeric IgG1k monoclonal antibody that neutralizes cytokine TNF-alpha and inhibits its binding to TNF-alpha receptor. Reduces infiltration of inflammatory cells and TNF-alpha production in inflamed areas. May be administered with or without methotrexate. |
| Adult Dose | 5 mg/kg IV infusion at 0, 2, and 6 wk as induction regimen, then 5 mg/kg q6wk for maintenance IV infusion must be administered over at least 2 h; must use infusion set with in-line, sterile, nonpyrogenic, low-protein-binding filter (pore size <1.2 µm) |
| Pediatric Dose | Not established |
| Contraindications | Documented hypersensitivity |
| Interactions | None reported |
| Pregnancy | C - Safety for use during pregnancy has not been established. |
| Precautions | TNF-alpha modulates cellular immune responses; anti-TNF therapies, such as infliximab, may adversely affect normal immune responses and allow development of superinfections; more cases of lymphoma were observed in TNF-alpha blockers compared with controlled groups; may increase risk of reactivation of tuberculosis in patients with particular granulomatous infections |
| Drug Name | Etanercept (Enbrel) |
|---|---|
| Description | Soluble p75 TNF receptor fusion protein (sTNFR-Ig). Inhibits TNF binding to cell surface receptors, thereby decreasing inflammatory and immune responses. |
| Adult Dose | 25 mg SC 2 times/wk |
| Pediatric Dose | Not established |
| Contraindications | Documented hypersensitivity; sepsis |
| Interactions | Do not administer within 3 mo of live virus vaccines (eg, MMR) |
| Pregnancy | B - Usually safe but benefits must outweigh the risks. |
| Precautions | Serious infections may develop and therapy should be discontinued if they occur; possible adverse effects include injection site pain, redness and swelling at injection site, and headaches; rare cases of lupuslike symptoms and heart failure have been reported (discontinue treatment if symptoms develop) |
| Drug Name | Adalimumab (Humira) |
|---|---|
| Description | Recombinant human IgG1 monoclonal antibody specific for human TNF. Indicated to reduce signs and symptoms in patients with active AS. Can be used alone or in combination with methotrexate or other disease-modifying antirheumatic drugs (DMARDs). |
| Adult Dose | 40 mg SC q2wk |
| Pediatric Dose | Not established |
| Contraindications | Documented hypersensitivity; active infection |
| Interactions | May interfere with immune response to live virus vaccine (MMR) and reduce efficacy; methotrexate decreases clearance (available data do not support adjusting dose of either adalimumab or methotrexate); coadministration with anakinra (an interleukin-1 antagonist that also blocks TNF) may cause additive adverse effects, particularly development of serious infections |
| Pregnancy | C - Safety for use during pregnancy has not been established. |
| Precautions | Causes immunosuppression; may reactivate tuberculosis infection; increases risk for lymphoma development; associated with CNS demyelination (rare); discontinue if serious infection develops; autoantibody development may occur causing lupuslike syndrome; may cause hypersensitivity reactions, including anaphylaxis and hematologic adverse effects (ie, pancytopenia, aplastic anemia) |
This agent relieves pain and joint swelling and treats GI lesions associated with inflammatory bowel disease.
| Drug Name | Sulfasalazine (Azulfidine, EN-tabs) |
|---|---|
| Description | Acts locally in colon to decrease inflammatory response; systemically inhibits prostaglandin synthesis. |
| Adult Dose | Initial dose: 1 g PO tid/qid Maintenance dose: 2 g/d PO divided tid/qid |
| Pediatric Dose | <2 years: Not established > 2 years: Initial dose: 40-60 mg/kg/d PO q4-8h Maintenance dose: 20-30 mg/kg/d PO divided qid |
| Contraindications | Documented hypersensitivity; hypersensitivity to sulfa drugs; GI or GU obstruction |
| Interactions | Decreases effects of iron, digoxin, and folic acid; increases effects of oral anticoagulants, methotrexate, and oral hypoglycemic agents |
| Pregnancy | B - Usually safe but benefits must outweigh the risks. |
| Precautions | Use caution in patients with renal impairment, blood dyscrasias, impaired hepatic function, or urinary obstruction; possible adverse effects include headache, sore throat, anorexia, nausea, jaundice, reversible oligospermia, itching, skin rash, hives, hemolytic anemia, and cyanosis; Monitor CBC and microscopic urinalysis frequently |
These agents relieve inflammation and joint pain associated with ankylosing spondylitis.
| Drug Name | Prednisone (Deltasone, Orasone, Sterapred) |
|---|---|
| Description | Decreases inflammation by suppressing migration of polymorphonuclear leukocytes and reversing increased capillary permeability. May be given PO or injected into an inflamed joint, which may afford temporary relief from pain, stiffness, and swelling. |
| Adult Dose | 5-60 mg/d PO qd or divided bid/qid; taper over 2 wk as symptoms resolve |
| Pediatric Dose | 4-5 mg/m2/d PO; alternatively, 1-2 mg/kg qd or divided bid/qid; taper over 2 wk as symptoms resolve |
| Contraindications | Documented hypersensitivity; diabetes; mental illness; hypothyroidism; cirrhosis; viral, fungal, or tubercular skin lesions |
| Interactions | Clearance may be decreased by estrogens; when used with digoxin, may increase digitalis toxicity secondary to hypokalemia; phenobarbital, phenytoin, and rifampin may increase metabolism (consider increase in maintenance dose of prednisone); monitor patients for hypokalemia when taking with diuretics |
| Pregnancy | B - Usually safe but benefits must outweigh the risks. |
| Precautions | Use caution in patients with hyperthyroidism, nonspecific ulcerative colitis, osteoporosis, peptic ulcer, and myasthenia gravis; abrupt withdrawal may cause adrenal crisis; possible adverse effects include hyperglycemia, edema, osteonecrosis, peptic ulcer disease, hypokalemia, osteoporosis, euphoria, psychosis, growth suppression, myopathy, and infections |
These agents are second-line therapy to control symptoms of joint pain and inflammation in ankylosing spondylitis.
| Drug Name | Methotrexate (Folex, Rheumatrex) |
|---|---|
| Description | Mechanism of action in ankylosing spondylitis unknown; may affect immune function. Although clearly ameliorates symptoms of inflammation, no evidence that it induces remission. |
| Adult Dose | 7.5 mg/wk PO as a single weekly dose or 2.5 mg PO q12h for 3 doses given as a course once weekly; in either schedule, dosages may be adjusted gradually to achieve optimal response; not to exceed 20 mg total weekly dose ordinarily Alternative: 0.2-0.4 mg/kg PO once weekly |
| Pediatric Dose | 5-15 mg/m2/wk PO/IM as single dose or as 3 divided doses given q12h |
| Contraindications | Documented hypersensitivity; alcoholism, alcoholic liver disease, or other chronic liver disease; laboratory evidence of immunodeficiency syndromes, preexisting blood dyscrasias such as bone marrow hypoplasia, leukopenia, thrombocytopenia, or significant anemia |
| Interactions | Concurrent NSAIDs may cause fatal interaction; oral aminoglycosides may decrease absorption and blood levels of PO methotrexate; charcoal lowers plasma levels of both PO and IV forms, which may be particularly significant with high-dose therapies; etretinate may increase hepatotoxicity; folic acid or its derivatives contained in some vitamins may decrease response to methotrexate; indomethacin and phenylbutazone can increase plasma levels (mechanism of action not known, but may involve inhibition of renal prostaglandin synthesis or competitive renal secretion); may decrease phenytoin serum concentrations; procarbazine many increase nephrotoxicity; may increase plasma levels of thiopurines Probenecid, salicylates, and sulfonamides (including TMP-SMZ) may increase therapeutic and toxic effects; inhibition of renal tubular secretion, competition for common elimination pathway, or protein displacement may be causes; however, if protein displacement is mechanism, may involve displacement of highly bound metabolic 7-hydroxymethotrexate, since parent drug is only 50% bound |
| Pregnancy | X - Contraindicated in pregnancy |
| Precautions | Monitor blood cell counts at least monthly; liver and renal functions, q1-3 mo during therapy; during initial or changing doses, or periods of increased risk of elevated methotrexate blood levels (eg, dehydration), more frequent monitoring may be indicated; stop methotrexate immediately if blood cell counts drop significantly; aspirin, NSAIDs, or low-dose steroids may be continued, although possibility of increased toxicity with concomitant NSAIDs (including salicylates) has not been fully explored Potential adverse effects include hepatotoxicity, interstitial pneumonitis, bone marrow suppression, severe nephropathy, opportunistic infections, ulcerative stomatitis, and diarrhea |
Ankylosing Spondylitis excerpt
Article Last Updated: Jan 8, 2007